Bone metastases from solid tumours - denosumab: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Denosumab for the treatment of bone metastases from solid tumours and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm, Friday 31 August
Bone metastases from solid tumours - denosumab: final appraisal determination guidance
Bone metastases from solid tumours - denosumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Bone metastases from solid tumours - denosumab: Consultee and commentator comments on the ACD
Bone metastases from solid tumours - denosumab: Comments on the ACD received from the public through the NICE website
This page was last updated: 16 August 2012